The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)

O. Baranova, O. Baklanova, V. Voinov (St. Petersburg, Russian Federation)

Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Session: Clinical aspects in the management of sarcoidosis
Session type: Thematic Poster Session
Number: 3450
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Baranova, O. Baklanova, V. Voinov (St. Petersburg, Russian Federation). The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS). Eur Respir J 2008; 32: Suppl. 52, 3450

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 85s
Year: 2007

Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021


Use of surfactant-BL (S-BL) in complex treatment of pulmonary TB patients
Source: Eur Respir J 2003; 22: Suppl. 45, 521s
Year: 2003

The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007


Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006

The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002

Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012

The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up)
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010


Isophonum usage in treatment of patients with pulmonary tuberculosis and accompanying pathology and elderly patients
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002

Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD)
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007


The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 72s
Year: 2006

Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009

The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 713s
Year: 2004

Effectiveness of pulmonary rehabilitation including occupational therapy (OT) on the prognosis of patients with COPD
Source: Annual Congress 2012 - New adjuncts and modalities in pulmonary rehabilitation
Year: 2012


Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Do results of T-SPOT.TB assays change during and after treatment of active tuberculosis?
Source: Annual Congress 2006 - New methods to diagnose tuberculosis infection
Year: 2006


The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008


Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020